摘要
目的评价阿帕替尼联合超选择性肝动脉化疗栓塞术(S-TACE)治疗中晚期原发性肝癌的疗效及安全性。方法根据随机数字表法将70例中晚期原发性肝癌患者分为对照组和观察组,每组35例。对照组采用S-TACE治疗,观察组采用S-TACE联合口服阿帕替尼治疗。比较两组患者的临床疗效、不良反应发生情况及治疗前后血清基质金属蛋白酶(MMP)-2、MMP-9、MMP-11、血管内皮细胞生长因子受体2(VEGFR2)水平。结果观察组患者治疗后的临床获益率为65.71%,明显高于对照组的34.29%(P﹤0.01);治疗后,观察组患者皮疹、高血压、手足综合征、蛋白尿的发生率均高于对照组,差异均有统计学意义(P﹤0.05),经对症处理后不良反应均缓解;治疗后,两组患者的血清MMP-2、MMP-9、MMP-11、VEGFR2表达水平均较本组治疗前降低,且观察组患者的血清MMP-2、MMP-9、MMP-11、VEGFR2表达水平均低于对照组,差异均有统计学意义(P﹤0.05)。结论阿帕替尼联合S-TACE治疗中晚期原发性肝癌有助于提高临床获益率,降低血清MMP表达水平,且安全性有保障。
Objective To evaluate the therapeutic effect and safety of apatinib combined with super-selection transcatheter arterial chemoembolization(S-TACE) as the treatment for patients with advanced hepatocellular carcinoma(HCC). Method According to the random number table, 70 patients with advanced HCC were included and divided into control group and study group, with 35 patients in each. The control group was treated with S-TACE, while the study group was administered with S-TACE combined with oral apatinib, the clinical efficacy, occurrence of adverse reactions and serum levels of matrix metalloproteinase(MMP)-2, MMP-9, MMP-11 and vascular endothelial growth factor receptor 2(VEGFR2) before and after treatment were compared between the two groups. Result The clinical benefit rate in study group after treatment was 65.71%, which was significantly higher than the 34.29% observed in control group(P<0.01). After treatment, the incidence of rash, hypertension, hand-foot syndrome and proteinuria were significantly higher in study group than in control group(P<0.05), and these adverse reactions were relieved after symptomatic treatment. After treatment, the expression levels of serum MMP-2, MMP-9, MMP-11 and VEGFR2 consistently decreased in both groups, and were significantly lower in study group compared to control group, with statistically significant differences observed(P<0.05). Conclusion The combined regimen of apatinib and S-TACE in the treatment of patients with advanced HCC can help to improve the clinical benefit rate, as well as decrease the serum MMP expression, demonstrating acceptable safety.
作者
翁志成
彭建扬
吴伟达
张春生
林群
潘喜鹏
WENG Zhicheng;PENG Jianyang;WU Weida;ZHANG Chunsheng;LIN Qun;PAN Xipeng(Department of Intervention,Affiliated Hospital of Fujian Putian University,Putian 351100,Fujian,China)
出处
《癌症进展》
2019年第22期2666-2669,共4页
Oncology Progress
基金
福建省自然科学基金（2018J0105）
关键词
阿帕替尼
S-TACE
中晚期原发性肝癌
疗效
安全性
apatinib
super-selection transcatheter arterial chemoembolization
advanced hepatocellular carcinoma
therapeutic effect
safety
作者简介
通信作者:翁志成,邮箱:1405103898@qq.com2666。
